Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 5/20 | 0.56 |
| ▸ | MMP3 | P08254 | 12/20 | 0.46 |
| ▸ | MMP1 | P03956 | 9/20 | 0.46 |
| ▸ | MMP2 | P08253 | 8/20 | 0.46 |
| ▸ | MMP7 | P09237 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | Q9HBH1 | 1/20 | 0.41 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Actinonin SCHEMBL279122 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| Actinonin SCHEMBL14490676 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| Actinonin SCHEMBL123273 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| Actinonin SCHEMBL12601775 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL6294118 | 0.97 | BIRC2 (0.55) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL18328823 | 0.92 | MMP3 (0.49) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL21387112 | 0.92 | BIRC2 (0.47) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL14279424 | 0.90 | BIRC2 (0.55) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL6294172 | 0.87 | BIRC2 (0.58) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL9495973 | 0.87 | BIRC2 (0.44) | BIRC2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710932-A1 | COMPOSITIONS COMPRISING MANGANESE FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE | Administración General de la Comunidad Autónoma de Euskadi (ES) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025226325-A2 | IN VITRO SYSTEMS FOR GENERATION OF SKIN EQUIVALENTS AND USES THEREOF AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONNECTIVE TISSUE DISORDERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-10-30 | — | — | WO | disclosed |
| CN-109851614-B | Heterocyclic peptide deformylase inhibitor and preparation method and application thereof | 中山大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-10377818-B2 | Method of treating glioma | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-20160222100-A1 | Method of Treating Glioma | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-8133514-B2 | Carbon-substituted diketopiperazine delivery systems | MANNKIND CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| WO-2009098451-A2 | BIOMARKERS OF AMINOPEPTIDASE INHIBITION | CHROMA THERAPEUTICS LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-7504436-B2 | Bioisosteres of actinonin | NOVARTIS AG (CH) | 2009-03-17 | — | — | US | disclosed |
| US-7504436-B2 | Bioisosteres of actinonin | NOVARTIS AG (CH) | 2009-03-17 | — | — | US | disclosed |
| WO-2008150089-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080008764-A1 | CARBON-SUBSTITUTED DIKETOPIPERAZINE DELIVERY SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7276534-B2 | Di-C-substituted diketopiperazines, e.g., the diketopiperazine of lysine, are carriers that facilitate the delivery, especially orally, of a wide variety of drugs | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070060624-A1 | Novel bioisosteres of actinonin | MORPHOCHEM AKTIENGESELLSCHAFAT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060624-A1 | Novel bioisosteres of actinonin | MORPHOCHEM AKTIENGESELLSCHAFAT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007003594-A1 | SCREENING METHODS FOR INHIBITORS OF THE METALLOPROTEASE MEPRIN | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | ANPEP, DNPEP, RNPEP | BIRC2 1935/4885MMP3 73/4885MMP1 85/4885 |
| US-20080008764-A1 | CARBON-SUBSTITUTED DIKETOPIPERAZINE DELIVERY SYSTEMS | PAICS, CRH, DHPS | BIRC2 186/4885MMP3 1593/4885MMP1 1024/4885 |
| US-20070060624-A1 | Novel bioisosteres of actinonin | ACTR3, ACTR2, ACTR5 | BIRC2 1790/4885MMP3 42/4885MMP1 38/4885 |
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | PDF, PEPD, DPEP1 | BIRC2 3414/4885MMP3 1031/4885MMP1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.